Eris Lifesciences to meet Franklin Templeton on May 29
Eris Lifesciences Limited announced a virtual investor meeting with Franklin Templeton scheduled for May 29, 2026. The session, led by Mr. Krishnakumar Vaidyanathan at 10:30 AM IST, will rely on publicly available documents and will not involve unpublished price sensitive information.

*this image is generated using AI for illustrative purposes only.
Eris Lifesciences Limited has announced that its management will participate in an investor conference with Franklin Templeton. The meeting is scheduled to take place virtually on Friday, May 29, 2026.
The interaction will be led by Mr. Krishnakumar Vaidyanathan, a management representative from the company. The session is set to begin at 10:30 AM IST and will be conducted in a one-on-one format.
Meeting Details
The following table outlines the specifics of the scheduled interaction:
| Day and Date | Fund Name | Management Representatives | Mode of Meeting | Meeting Details |
|---|---|---|---|---|
| Friday, May 29, 2026 | Franklin Templeton | Mr. Krishnakumar Vaidyanathan | Virtual | 10:30 AM IST, 1X1 |
The company has clarified that the schedule provided is indicative and subject to change due to unforeseen developments. During the meeting, the management will refer to publicly available documents for discussions.
Eris Lifesciences Limited emphasized that no unpublished price sensitive information (UPSI) is intended to be discussed during the interaction. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.58% | +1.89% | -0.88% | -15.79% | -11.68% | +95.14% |
What key strategic priorities is Eris Lifesciences likely to highlight during the Franklin Templeton conference?
How might the insights shared by Mr. Vaidyanathan influence investor sentiment toward Eris Lifesciences?
Could this meeting signal potential collaborations or increased interest from Franklin Templeton in Eris Lifesciences?


































